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Hyperglycemia, in both diabetic and nondiabetic patients, has a signiﬁcant negative impact on the morbidity and mortality of
patients presenting with an acute myocardial infarction (AMI). Contemporary evidence indicates that persistent hyperglycemia
after initial hospital admission continues to exert negative eﬀects on AMI patients. There have been a number of studies
demonstrating the beneﬁt of tight glucose control in patients presenting with AMI, but a lack of convincing clinical data has
led to loose guidelines and poor implementation of glucose targets for this group of patients. The CREATE-ECLA study, which
hypothesized that a ﬁxed high dose of glucose, insulin, and potassium (GIK) would change myocardial substrate utilization from
free fatty acids to glucose and therefore protect ischemic myocardium, failed to demonstrate improved clinical outcomes in AMI
patients. Studies that speciﬁcally investigated intensive insulin therapy, including DIGAMI-2 and HI-5, also failed to improve
clinical outcomes such as mortality. There are a number of reasons that these trials may have fallen short, including the inability to
reach glucose targets and inadequate power. There is now a need for a large placebo-controlled randomized trial with an adequate
sample size and adherence to glucose targets in order to establish the beneﬁt of treating hyperglycemia in patients presenting with
AMI.
1.Background
Major advances in cardiovascular disease, and speciﬁcally
the treatment of acute coronary syndrome (ACS), have
had a signiﬁcant impact on the morbidity and mortality of
patients with acute myocardial infarctions (AMI). Despite
these advances, diabetes continues to put patients with and
withoutapriorhistoryofmyocardialinfarctionatsigniﬁcant
cardiovascular risk [1]. The presence of diabetes doubled
the age-adjusted risk for cardiovascular disease in men and
tripled it in women in the Framingham Heart Study, and
it remained an independent risk factor even after adjusting
for age, hypertension, smoking, hyperlipidemia, and left
ventricular hypertrophy [2]. Furthermore, there is a graded
rise in cardiovascular risk with increasing hyperglycemia
in patients with overt diabetes. In fact, as demonstrated by
a meta-analysis of 13 prospective cohort studies, for every
one-percentage point increase in glycosylated hemoglobin
(HbA1c), the relative risk for any cardiovascular event was
1.18 (95% CI 1.10–1.26) [3].
It has been well documented that with adequate glycemic
control, cardiovascular outcomes improve in patients with
both type 1 and type 2 diabetes [4]. Interestingly, intensive
glycemic control does not have the same eﬀect, particularly
in long-standing type 2 diabetics. In the ACCORD study,
10,250 patients with long-standing type 2 diabetes were2 Cardiology Research and Practice
randomly assigned to either intensive or standard glycemic
control. After a median followup of 3.7 years, intensive
therapy was discontinued due to a higher number of total
and cardiovascular deaths in subjects assigned to intensive
therapy (median HbA1C 6.4 percent) compared with the
standard treatment group (median HbA1C 7.5 percent) [5].
This raises the question: what are the eﬀects of
hyperglycemia, standard glycemic control, and intensive
glycemic control in the setting of acute myocardial infarction
and/or acute coronary syndrome? How do these eﬀects
diﬀer in long-standing diabetic and nondiabetic popula-
tions? While there has been extensive study in the area of
hyperglycemia and cardiovascular outcomes in AMI, there
is no consensus regarding blood glucose targets and the
beneﬁts of treating hyperglycemia in this setting. This in
turn is leading to poor control of blood glucose in the AMI
setting, an area where further studies could yield signiﬁcant
improvement in cardiovascular outcomes.
2. The Prognostic Role of Glucose Values in
AcuteMyocardialInfarction
The prevalence of admission hyperglycemia (glucose levels
of >140mg/dL) in diﬀerent epidemiological studies ranges
from 51% to >58% of patients admitted with AMI [6]. In
patients with AMI, hyperglycemia at the time of admission
regardless of diabetic status has been tied to both long-
and short-term negative outcomes [7, 8]. A number of
contemporary investigators, however, have challenged this
notion and demonstrated that hyperglycemia after hospital
admission may yield a more important prognostic role
than admission hyperglycemia in terms of morbidity and
mortality [9, 10]. Suleiman and colleagues, for instance,
were able to demonstrate that fasting glucose was superior
to admission glucose in predicting 30-day mortality in
735 nondiabetic AMI patients [11]. Loomba and Arora
performed an extensive systemic review and were able to
demonstrate that persistent glucose levels oﬀer a better
model to predict ACS mortality than on-admission glucose
levels[12].Ithasbeendemonstratedthattheuseofinsulinto
lowerglucoseconcentrationsdecreasednegativeoutcomesin
patients with hyperglycemia and myocardial infarction (see
Section 3); however, a mechanism by which hyperglycemia
may be a causal factor in poor outcomes in AMI remains
a topic of debate. It has been proposed that in AMI
patients, decreased levels of blood insulin associated with
hyperglycemia may lead to a decrease of glycolytic substrate
for cardiac muscle. As a result, the heart has to depend on
alternatesubstratessuchasfreefattyacidsforitsmetabolism.
The accumulation of excessive free fatty acids results in the
reductionofmyocardialcontractilityandincreasestheriskof
pumpfailureandarrhythmias(Figure 1). Thischallengesthe
assumption that hyperglycemia is simply a “marker” of the
stress response mediated by cortisol and noradrenaline [13].
A meta-analysis by Capes and colleagues in 2000 supported
this hypothesis by demonstrating that among nondiabetic
patients, those with glucose concentrations between 110 and
143mg/dL had a 3.9-fold higher risk of death and that
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Figure 1: Hyperglycemia and its eﬀect on cardiac function.
those with glucose values between 144 and 180mg/dL had
a 3-fold higher risk of heart failure or cardiogenic shock.
Similarly, diabetics with glucose concentrations between 180
and 196mg/dL had an increased risk of death (relative risk
1.7) [7].
In addition to decreased contractility, pump failure, and
arrhythmia, hyperglycemia in AMI may aﬀect coronary per-
fusion prior to and following percutaneous coronary inter-
vention (PCI). A 2005 observational analysis by Timmer and
colleagues sought to determine how hyperglycemia aﬀected
coronary perfusion prior to revascularization in ST-segment
elevation myocardial infarction (STEMI) [14]. In 460 con-
secutive patients with STEMI who were treated with PCI,
70% had serum glucose levels ≥140mg/dL (7.8mmol/L) on
admission, but only 14 percent had a history of diabetes.
They were able to demonstrate that the patients with
hyperglycemia were signiﬁcantly less likely to have TIMI
grade 3 (normal) ﬂow prior to PCI compared to those
with normoglycemia (Table 1). This ﬁnding complements
those by Lazerri and colleagues in 2010, who were able
to demonstrate that glucose serum levels measured after
mechanicalrevascularizationwereindependentpredictorsof
in-hospital mortality in STEMI patients without previously-
known diabetes [15]. Indeed, acute hyperglycemia has been
associated with increased platelet activation in diabetic and
nondiabetic patients [16]; coupled with evidence that acute
hyperglycemia increases inﬂammatory responses during
STEMI [17, 18], these ﬁndings could explain an impairment
in coronary ﬂow that reﬂects a prothrombotic state and/or
endothelial dysfunctionassociated withhyperglycemia,lead-
ing to a greater stress response.Cardiology Research and Practice 3
Another interesting aspect of the prognostic value of
hyperglycemia in AMI is the diﬀerences observed in non-
diabetic and diabetic patients. In their 2011 study, Lazerri
and colleagues observed that in a cohort of STEMI patients
undergoing mechanical revascularization, in-hospital peak
glycemia was an independent predictor for early death in
patients without previously known diabetes, but not in
diabetic STEMI patients. At followup, in hospital peak
glycemia was able to aﬀect long-term survival in both
diabetic and nondiabetic patients. This data underscores
the clinical importance of the prognostic role of in-hospital
glucose values and strongly suggests that diﬀerent glucose
targets and thresholds may be pursued in diabetic and
nondiabetic STEMI patients [19].
3. Glycemic Control inPatients
with AcuteMyocardialInfarction
Controlling hyperglycemia during AMI admissions has been
the target of a great deal of basic and clinical research, with
results primarily trending toward a beneﬁt. The optimal
“glucose target” has been elusive, and contemporary guide-
lines reﬂect this [20, 21]. A prospective study of 32 patients
demonstrated that insulin infusion reduced inﬂammatory
and clotting mediators in the plasma, with a concomitant
reduction in enzymatic infarct size in subjects with STEMI
receiving ﬁbrinolytics [22]. Recent experimental data also
supports the beneﬁcial eﬀects of insulin infusion among
patientswithAMI.Wongandcolleagueswereabletodemon-
strate that insulin started 5 minutes prior to reperfusion
in white rabbits signiﬁcantly reduced infarct size following
regional ischemia and reperfusion in a dose-dependent
manner [23].
Although this data looks promising, previous large
prospectivestudiesofinsulininAMIhaveresultedinvarying
levels of beneﬁt. Many of these studies involved infusion of
a ﬁxed high dose of glucose, insulin, and potassium (GIK)
to change myocardial substrate utilization from free fatty
acids to glucose. It was hypothesized that this, in turn, would
protect the ischemic myocardium [24, 25]. In the CREATE-
ECLA study, which enrolled 20,000 patients, this GIK regi-
men did not demonstrate improved outcomes in AMI [26].
In this trial, 40% of the total subjects became hyperglycemic
(>144mg/dl) in the postrandomization period; of these,
the majority (62%) were in the GIK group. Subjects with
a postrandomization glucose of >144mg/dl had a 2.5-fold
higher risk of mortality compared to subjects with a glucose
<126mg/dl. While GIK was associated with a signiﬁcant
reduction in mortality and heart failure at 30 days after MI,
the overall eﬀect was neutralized by an increase in mortality
and heart failure with this regimen in the immediate 3-
day post-MI period. This initial increase in poor outcomes
was likely mediated by the fact that GIK infusion frequently
induced hyperglycemia and volume overload, which may
havemitigatedthebeneﬁcialeﬀectsofinsulinintheregimen.
Apart from GIK regimens, there have been other studies
thathaveinfusedinsulininhyperglycemicpatientswithAMI
with the intent to reduce glucose, including the DIGAMI,
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Figure 2: (a) Mortality beneﬁt of intensive insulin therapy over
conventional therapy in clinical trials. (b) Reduction in 24 hour
blood glucose levels with intensive insulin therapy over conven-
tional therapy in clinical trials.
DIGAMI-2 and HI-5 trial. While the DIGAMI study was
able to demonstrate a decrease in both mortality and mean
24-hour blood glucose levels, the DIGAMI-2 and HI-5
studies showed no such signiﬁcant decrease (Figure 2)[ 27–
29]. Importantly, the varying glucose target levels of these
studies make it diﬃcult to compare their results and infer a
ﬁrm conclusion. Of note, blood glucose levels in these trials
were not adequately lowered, the trials were underpowered
to show an eﬀect on mortality, and the infusions were
started more than 6 hours after symptom onset, when it
may have been too late to salvage the myocardium. Despite
these shortcomings, insulin infusion was shown to lower the
risk of heart failure (absolute risk reduction of 10%) and
reinfarction (absolute risk reduction of 3.4%) [27, 29].4 Cardiology Research and Practice
Table 1: Initial TIMI ﬂow grade according to admission glucose. Worse initial Thrombolysis in Myocardial Infarction (TIMI) ﬂow grade is
demonstrated in those with hyperglycemia.
Glucose <7.8mmol/L (<140mg/dL) Glucose ≥7.8mmol/L (≥140 mg/dL) P value
TIMI ﬂow grade 3 38 (28%) 38 (12%) <0.001∗
TIMI ﬂow grade 2 32 (23%) 65 (20%)
TIMI ﬂow grade 1 7 (5%) 42 (13%)
TIMI ﬂow grade 0 61 (44%) 177 (55%) 0.03†
∗As compared to TIMI ﬂow grade 2 to 0.
†As compared to TIMI ﬂow grade 1 to 3.
Table from [14].
Table 2: Recommendations for intensive glucose control in STEMI.
2004/2005/2007 recommendations:
2004 STEMI guidelines 2009 joint STEMI/PCI focused update recommendations Comments
Class I
(1) An insulin infusion to normalize
blood glucose is recommended for
patients with STEMI and complicated
courses (level of evidence: B).
Recommendation is no longer
current. See 2009 Class IIa
recommendation no. 1.
Class IIa
(1) It is reasonable to use an insulin-based regimen to
achieve and maintain glucose levels less than 180mg/dL while
avoiding hypoglycemia∗ for patients with STEMI with either
a complicated or uncomplicated course (16, 94–96) (level of
evidence: B).
New recommendation
(1) During the acute phase (ﬁrst 24 to
48 hours) of the management of STEMI
in patients with hyperglycemia, it is
reasonable to administer an insulin
infusion to normalize blood glucose
even in patients with an uncomplicated
course (level of evidence: B).
Recommendation is no longer
current. See 2009 Class IIa
recommendation no. 1.
∗There is uncertainty about the ideal target range for glixose necessary to achieve an optimal risk-beneﬁt ratio.
Recommendations for Intensive Glucose Control in STEMI.
Table from [20].
4. Future Directions and Areas of
Further Study
The beneﬁt of insulin infusion in patients with hyper-
glycemia in ACS has yet to be demonstrated convincingly
in a large prospective clinical trial. While there is signiﬁcant
evidence that admission and postadmission hyperglycemia is
associated with increased mortality and morbidity in AMI,
there is no consensus regarding the targets and the beneﬁts
of treating hyperglycemia in this setting. This is illustrated
by the 2009 ACC/AHA focused update on STEMI, which
makes a rather weak recommendation (Table 2) for the use
of an insulin-based regimen to achieve and maintain blood
glucoselevelsbelow180mg/dL(10mmol/L),consistentwith
the 2007 update by Antman and colleagues (level of evidence
B) [20, 21]. It should be noted this recommendation does
not discriminate based on prior diabetes history. Similarly,
Kosiborod and colleagues, who performed an extensive
review on the topic of hyperglycemia and AMI, have recom-
mended glucose treatment targets within the “conservative
range” of 140–180mg/dl [30]. This falls within the range
demonstrated to be beneﬁcial by Lazerri and colleagues, who
in 2010 demonstrated in 252 nondiabetic STEMI patients
undergoingmechanicalrevascularization,thatpeakglycemia
>180mg/dl was associated with the elevated mortality,
whereas patients with peak glycemia comprised between 140
and 180mg/dl exhibited attenuated mortality rates [19].
If the lowering of glucose levels with insulin infusion
can demonstrate a reduction in adverse cardiac outcomes
over and above the beneﬁts provided by reperfusion therapy,
it would be a signiﬁcant improvement in the management
of ACS in the reperfusion era. Indeed, this was reﬂected
in a 2008 AHA statement on hyperglycemia in ACS, where
the guidelines emphasized the need for a large prospec-
tive randomized study examining this issue. Speciﬁcally, it
recommends randomized multicenter trials which should
include hyperglycemic patients both with and without
preexisting diabetes (suggested deﬁnition is plasma glucose
>140mg/dL at admission), should use safe and eﬀective
protocols for glucose control, and should aﬀord suﬃcientCardiology Research and Practice 5
statistical power to assess mortality as a primary outcome
[31].
5. Conclusion
While signiﬁcant advances have been made in the treatment
and prevention of cardiovascular disease, hyperglycemia in
the setting of acute myocardial infarction remains an area
where aggressive therapy could lead to a signiﬁcant improve-
ment in outcomes. Current guidelines stipulate a blood
glucose goal of 180mg/dL with the use of an insulin-based
regimen in the setting of AMI; however, a more aggressive
target has not been universally recommended primarily due
to lack of convincing evidence. While observational and
small prospective studies, as well as experimental data, have
demonstrated a beneﬁt in driving down a glucose target
using insulin infusion [12], a randomized trial with an
adequate sample size and stringent adherence to glucose
goals is now necessary.
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